July 09, 2022
Alpelisib Plus Fulvestrant in Patients With HR+, HER2− Advanced Breast Cancer
Journal of Clinical Oncology ascopubs.org/doi/abs/10.120...
TAKE-HOME MESSAGE
This biomarker analysis of the SOLAR-1 trial showed that alpelisib plus fulvestrant had a clinical benefit regardless of the gene mutation status in patients with HR+, HER2− advanced breast cancer (ABC), including those with FGFR1 or FGFR2 alterations. A limited benefit of alpelisib was noted in patients with the MYC mutation compared with placebo.
The clinical benefit with alpelisib plus fulvestrant was maintained in this patient population, regardless of alterations in most biomarkers, including ESR1 and genes implicated in CDK4/6i resistance (eg, CCND1, MAP3K1, and FGFR).
– Jing Xi, MD, MPH